ECCMID

Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials

Retrieved on: 
Thursday, April 20, 2023
Ertapenem, IV, Infection, Cutis verticis gyrata, Congress, ECCMID, Patient, European, ITRM, Ciprofloxacin, Therapy, Poster, DOOR, Pharmaceutical industry

The posters presented at ECCMID were:

Key Points: 
  • The posters presented at ECCMID were:
    The desirability of outcome ranking (DOOR), not yet accepted by regulatory authorities as a primary endpoint for urinary tract infection studies, is a novel method of analyzing data from clinical trials taking into account both benefits and harms of drugs being evaluated and providing an assessment of the patient experience.
  • It was utilized recently by the Antibacterial Resistance Leadership Group (ARLG) to develop a method to evaluate data from completed pivotal cUTI trials.
  • “Applying the ARLGs approach retrospectively to our two Phase 3 studies of sulopenem, one each in cUTI and uUTI, respectively, demonstrated that oral sulopenem was comparably more effective than ciprofloxacin in patients with uUTI and provided comparable efficacy to ertapenem in patients with cUTI,” said Dr. Sailaja Puttagunta, Chief Medical Officer of Iterum Therapeutics.
  • These Posters are available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab.

ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens

Retrieved on: 
Thursday, April 20, 2023
Neutropenia, Stenotrophomonas maltophilia, Interim, XDR, S. aureus, Serum, EM, Cell wall, Hope, Escherichia coli, Staphylococcus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Congress, Amikacin, ECCMID, Animal, Lower respiratory tract infection, Patient, European, ESKAPE, Ventilator-associated pneumonia, Immune system, Annual general meeting, Public, Fungal infection, Mortality, Campaign, Immunodeficiency, CF, Enterobacter cloacae, Infection, Peptide, Vaccine, MD, Pseudomonas

“The data presented on CF-370 at ECCMID should not be understated.

Key Points: 
  • “The data presented on CF-370 at ECCMID should not be understated.
  • Amikacin alone did not demonstrate a significant reduction in bacterial density in the lungs compared to the vehicle controls (as expected for this amikacin-resistant strain).
  • However, a single dose of CF-370 alone, and in addition to amikacin, significantly reduced bacteria counts compared to vehicle controls.
  • In this in vitro study, exebacase was profiled against clinical Staphylococcus aureus (S. aureus) isolates from patients with CF.

Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

Retrieved on: 
Wednesday, April 19, 2023
ISLAND, VRE, Clostridioides difficile infection, DNA, DNA-binding protein, University, IV, Flagellum, Public, IIIC, MRSA, Infection, Genetically modified bacteria, Houston Community College, Solubility, DRSP, Movement, Congress, Professor, ECCMID, Vancomycin, European, Metronidazole, University of Houston, Fidaxomicin, Susceptibility, Poster, Principal, Pharmacology, Recurrence, Virulence, Safety, Microbiology, Vaccine, Pharmacy

C. difficile strains with reduced susceptibility to metronidazole, vancomycin, or fidaxomicin were susceptible to ibezapolstat, confirming its unique mechanism of action.

Key Points: 
  • C. difficile strains with reduced susceptibility to metronidazole, vancomycin, or fidaxomicin were susceptible to ibezapolstat, confirming its unique mechanism of action.
  • To study anti-virulence effect, our group investigated an under-studied virulence property of C difficile, namely, flagellar movement of the organism.
  • All of these positive and unexpected findings reflect the unique mode of action in inhibiting DNA pol IIIC and support the continued development of ibezapolstat to treat C. difficile infection."
  • The poster and presentation are available on the Company's website www.acurxpharma.com.

Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID

Retrieved on: 
Tuesday, April 18, 2023
Infection, Nephrotoxicity, University, Fungal infection, Amputation, Foot, LNC, Doctor of Philosophy, Congress, ECCMID, MD, Patient, Division, Risk, Microsoft Access, European, Internal medicine, Yeast, Kidney, Toxic leukoencephalopathy, NYSE, Pharmaceutical industry, Raid on Matina, Rhodotorula

“We are extremely pleased with the positive clinical impact that MAT2203, oral amphotericin B, had on an extremely ill patient with very limited treatment options,” said Dr. Miceli.

Key Points: 
  • “We are extremely pleased with the positive clinical impact that MAT2203, oral amphotericin B, had on an extremely ill patient with very limited treatment options,” said Dr. Miceli.
  • mucilaginosa infection is rare and challenging to treat, due to innate antifungal resistance requiring long-term amphotericin B treatment, which historically leads to significant nephrotoxicity.
  • As a result, treatment with IV-amphotericin B was discontinued and Dr. Miceli applied to Matinas’ Compassionate Use Expanded Access Program for treatment with MAT2203.
  • The patient received MAT2203 daily for six months and ended therapy in January 2023 following complete clinical resolution of the fungal infection while regaining the use of her foot.

Ondine Biomedical’s Nasal Photodisinfection Cuts Surgical Site Infections by 66%

Retrieved on: 
Tuesday, April 18, 2023
Surgery, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, S. aureus, Christianity in Singapore, MRSA, LON, Fungus, Staphylococcus aureus, Centers for Disease Control and Prevention, SSI, CDC, Nose, Congress, ECCMID, Patient, European, Risk, Disease, Mortality, Virus, Infection, Pharmaceutical industry

The results indicate that patients who underwent Ondine’s nasal photodisinfection prior to surgery experienced 66% fewer surgical site infections (SSIs) than the US national average.

Key Points: 
  • The results indicate that patients who underwent Ondine’s nasal photodisinfection prior to surgery experienced 66% fewer surgical site infections (SSIs) than the US national average.
  • Of the 313 patients who underwent the treatment prior to surgery, 21% were found to have S. aureus colonization in their nose.
  • All patients in the study were treated with a single, 5-minute treatment of Ondine’s nasal photodisinfection, which eliminates infection-causing bacteria, viruses and fungi in the nose.
  • Ondine’s nasal photodisinfection is a patented technology which uses a proprietary, non-antibiotic photosensitizer to destroy pathogens.

Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)

Retrieved on: 
Monday, April 17, 2023
Vaccine, HIV, Vaccination, SARS-CoV-2, TCE, EVP, Gritstone bio, COVID-19, African, Immunity, NSP, NAB, AstraZeneca, Messenger, Congress, ECCMID, A6, European, Immune system, Immunoglobulin G, Epitope, Infection, A3, A1, A5, Capsid, A2, Delta, A4, New Data Seal, Gritstone

EMERYVILLE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented 6-month follow up data from its ongoing Phase 1 CORAL-CEPI and CORAL-BOOST studies, which are evaluating the company’s self-amplifying mRNA (samRNA) vaccine candidates against SARS-CoV-2, at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark.

Key Points: 
  • “Previously, we reported initial 6-month data from CORAL-BOOST showing sustained high neutralizing antibody levels in the boost setting following Vaxzevria (AstraZeneca) primary series.
  • “Current vaccines against COVID-19 have demonstrated susceptibility to loss of immunity over time, posing a greater burden on individuals and our health systems.
  • Designation as virus-naïve/convalescent was driven by baseline anti-Nucleocapsid (N) IgG serology status (negative/positive respectively).
  • To view Gritstone’s ECCMID presentations, visit ir.gritstonebio.com/investors/events .

Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023

Retrieved on: 
Monday, April 17, 2023
Biotechnology, FDA, Health, General Health, Pharmaceutical, Other Science, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, Online, Abstract, University, Fatigue, Honours degree, Health care, Food, Policy, AFHEA, Phosphocreatine, Quality of life, Medication, Infection, COVID, European Congress of Radiology, Trial of the century, Plasma, ECCMID, Patient, EMM, Division, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, University of Oxford, MHRA, Disease, Pharmaceutical industry, Long COVID, Lancet

This was a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.

Key Points: 
  • This was a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID.
  • Lancet eClinical Medicine published the trial results on April 14, 2023 ( eClinicalMedicine 2023; April 14: 101946, Published Online ).
  • The MHRA provided regulatory guidance supporting a single trial that could serve as the registration trial for patients with Long COVID Fatigue.
  • “We are excited to see two oral presentations of abstracts from our Phase 2a clinical study of AXA1125 in Long COVID fatigue at ECCMID, along with publication of the results in the Lancet, one of the premier medical journals,” said Margaret Koziel, M.D., Chief Medical Officer of Axcella.

PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

Retrieved on: 
Monday, April 17, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Clostridioides difficile infection, LSE, JAMA, CDI, Mayo Clinic, Clostridioides, PureTech Health, Definition, Inflammation, Biomarker, European Congress of Ethnic Religions, Homeostasis, Microbiota, American Medical Association, Journal, ECCMID, User experience, Patient, Division, Risk, Hepatology, Variometer, Biology, Growth, Recurrence, Clinical professor, PRTC, Safety, Pharmaceutical industry, Dentistry, Vedanta, Gastroenterology

The study data confirmed that VE303 prevented recurrent Clostridioides difficile infection (CDI) compared with placebo in the study population.

Key Points: 
  • The study data confirmed that VE303 prevented recurrent Clostridioides difficile infection (CDI) compared with placebo in the study population.
  • The ECCMID presentation offers more in-depth scrutiny of VE303 strain colonization dynamics and its relationship to the observed clinical effect.
  • The ECCMID presentation offers more in-depth scrutiny of VE303 strain colonization dynamics and its relationship to the observed clinical effect.
  • This analysis demonstrates the possibility that VE303 may provide benefit beyond microbiome restoration in patients with CDI, by limiting pathological inflammation.

Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

Retrieved on: 
Monday, April 17, 2023
Health, Clinical Trials, General Health, Research, Pharmaceutical, Science, Clostridioides difficile infection, JAMA, CDI, Mayo Clinic, Clostridioides, Definition, Inflammation, Biomarker, European Congress of Ethnic Religions, Homeostasis, Microbiota, American Medical Association, Journal, ECCMID, User experience, Patient, Division, Risk, Hepatology, Variometer, Biology, Growth, Recurrence, Clinical professor, Safety, Pharmaceutical industry, Vaccine, Vedanta, Gastroenterology

The ECCMID presentation offers more in-depth scrutiny of VE303 strain colonization dynamics and its relationship to the observed clinical effect.

Key Points: 
  • The ECCMID presentation offers more in-depth scrutiny of VE303 strain colonization dynamics and its relationship to the observed clinical effect.
  • Colonization dynamics is analogous to traditional drug pharmacokinetics and refers to the growth and persistence over time of bacterial strain populations in the human gut.
  • “First-generation microbiome approaches use fecal donor material of variable composition, resulting in inconsistent efficacy outcomes across different clinical studies.
  • This analysis demonstrates the possibility that VE303 may provide benefit beyond microbiome restoration in patients with CDI, by limiting pathological inflammation.

Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

Retrieved on: 
Monday, April 17, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, PK, Tissue, Heart, Rat, Gland, Macrophage, Epithelium, COVID-19, Bella Center Copenhagen, Brain, Adipocyte, Lung, Medication, Plasma, Congress, RSV, ECCMID, Patient, European, Dog, Viral, Kidney, Mouse, Adipose tissue, Caco-2, Potential, Treatment, Infection, Vaccine, SPRINT

EDP-235 is currently being evaluated in SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 study of non-hospitalized, symptomatic adults with mild or moderate COVID-19.

Key Points: 
  • EDP-235 is currently being evaluated in SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 study of non-hospitalized, symptomatic adults with mild or moderate COVID-19.
  • Enanta continues to expect topline data from the study in May 2023.
  • EDP-323 is currently being evaluated in a Phase 1 double-blind, placebo-controlled, first-in-human study with a topline data readout planned for the second quarter of 2023.
  • These preclinical data support the potential of EDP-323 as a convenient, once-daily oral treatment for RSV.